THE BUCHAREST UNIVERSITY OF ECONOMIC STUDIES

Doctoral School of Management

PhD Thesis

Presented and publicly supported by the author:

BENJAMIN HERNANDEZ FRANCO

Title of the PhD Thesis:

Intellectual property assets and technology transfer of biologics and biosimilars: Application and comparative study to the United States of America and Romania

Academic Advisor: Professor PhD CRISTIAN-SILVIU BANACU

PhD Thesis Committee:

Professor PhD Cezar Simion (President) - The Bucharest University of Economic Studies
Professor PhD Adriana Burlea-Șchiopoiu (Reviewer) - Craiova University
Professor PhD Constanta Popescu- (Reviewer)- Valahia University Targoviste
Professor PhD Claudiu-Constantin Cicea (Reviewer) - The Bucharest University of Economic Studies
Professor PhD Cristian-Silviu Banacu (Academic Advisor) - The Bucharest University of Economic Studies

Bucharest, September 2024

TABLE OF CONTENTS

Keywords: Management of Technology, intellectual property, biologics, biosimilars, biologic and biosimilar market pricing, pharmaceutical management.

ABSTRACT

The Management of Technology (MOT) is a critical factor in the success of business, particularly in industries driven by technological dynamism and heavy regulatory pressures. At the heart of MOT lies Intellectual Property (IP) management, which ensures protection for innovation while driving competitive advantages that influence the market environment. Within the pharmaceutical industry, specifically covering biologics and biosimilars, effective IP management and related technologies are critical to sustaining market leadership for continued innovation. This thesis probes into the interplay between MOT practice and its market outcomes within the biologics and biosimilars industries to shed light on how regulatory environments, pricing strategies, and IP management impinge upon market dynamics across the United States and Europe.

Based on the supposition that robust management practices, including clear performance standards, innovation, and strategic IP management, significantly impact market entry and pricing behavior, this research is justified in employing a holistic mixed-methods approach. It integrates a review of the literature, an analysis of data from US and European markets, and a survey of 247 industry professionals to determine the effect that MOT has on competitive positioning regarding biologics and biosimilars. Quantitative methods were used using chi-square tests of independence, econometric models, and Monte Carlo simulations to determine demographic variable correlations with pricing strategies and perceived management stability.

The results of this study indicate that, although biologics retain premium pricing, the entrance of biosimilars has not consistently spurred anticipated price reductions in the US market, especially for autoimmune and oncology agents, as seen in contrast to what happens in the European market where legislative measures and IP regime has led to substantial price decreases and wider market penetration for biosimilars. The study also suggests that pharmaceutical management perceptions of pricing strategies and management stability are not significantly influenced by demographic characteristics; hence, organizational culture and strategic management practice might play a more crucial role in shaping those perceptions.

This research contributes uniquely to the MOT field by offering rigorous analysis of how IP management, regulatory environments, and market dynamics play out in the complex environment of the pharmaceutical industry. It extends current knowledge by explaining that

differences in regulatory approaches between the US and Europe create distinct market conditions that influence biosimilar success and pricing. The findings have important implications for industry practitioners and policymakers in terms of IP management strategies that would enhance innovation and competitive market conditions, beneficial to companies, as well as consumers. Policy reforms are recommended for enhancing biosimilar approval processes, fostering market competition, and improving access to affordable medication; thus, ultimately resulting in better healthcare outcomes.

This study provides a comprehensive analysis of MOT in the pharmaceutical field, emphasizing the importance of strategic IP management and regulatory alignment in driving market success. The research offers actionable insights and recommendations that are essential for advancing the MOT in industries where innovation and regulatory compliance are critical to sustaining competitive advantage. It provides pragmatic insights and recommendations required to advance technology management in industries that consider innovation and regulatory compliance.

THESIS SUMMARY

INTRODUCTION

This thesis researches into the core of intellectual property management and management of technology issues within the biopharmaceutical sector. More precisely, the research concerns two categories of pharmaceutical products vital to contemporary medicine: biologics and biosimilars. Evidence on how these aspects interact under different regulatory settings will be discussed, especially in the US and Romania, and how they drive market dynamics, competitive positioning, and eventually access to these essential medicines.

LITERATURE REVIEW

The literature review looks at the theoretical underpinnings of technology management, intellectual property rights, and an application within the pharmaceutical sector. It discusses such important concepts as innovation, competitive advantage, and regulatory frameworks as determinants of market dynamics. It also considers those that make up the existing body of research on biologics and biosimilars, indicating what gaps and problems the present thesis is going to solve.

Innovation and its relationship with IP management constitute one of the central themes in the literature. Granstrand (1999) and Chesbrough (2003) have argued that innovation needs to be sustained by protecting intellectual assets. In industries such as pharmaceuticals, where new product development involves huge R&D outlays, as a vital component for protecting ownership effective IP management is very important for sustenance of competitive advantages. Evidence has been provided in the literature on challenges related to handling biosimilars from IP dimensions considering molecules' complexity and the prerequisite need for extensive clinical trials acting as an entry barrier.

The review discusses how different regulatory environments impact the dynamics of the market, with special comparisons between the United States and Europe on the works of scholars such as Maskus (2000) and Jaffe & Lerner (2004). Evidence is provided in these studies for

substantial differences in the approval process for biosimilars, with the European Union having adopted a much simpler approach, thus speeding products into the market more quickly. On the other hand, the United States has been more careful in this arena and has required more from manufacturers, with final guidance from FDA including requirements for additional data and clinical trials to ensure safety and efficacy on top of what was available.

The literature review has it that it also looks into the role of technological advancements. The pharmaceutical industry integrates advanced technologies in their manufacturing and quality control to ensure that products are of high standards, safe and effective besides meeting regulatory requirements. Evidence is found in papers by Pisano (2006) and others highlighting the importance of technological innovation for competitive advantage sustenance in the pharmaceutical industry.

Data Utilized in the Research

The data used in this thesis is multidimensional, comprising both quantitative and qualitative aspects. It is based on the literature review, market analysis, and primary empirical information based on a survey of 247 professionals in this field who give their opinion on technology management practice variables that affect the competitive placement of biologics and biosimilars. Survey data were also accompanied by case studies from major biopharmaceutical companies that further illustrated IP management and technology transfer in action. Also considered were market data from the United States and Europe relating to pricing strategies, market penetration, and regulatory impact.

RESEARCH METHODOLOGY

The methodology used in this thesis is a mixed-methods approach that integrates both quantitative and qualitative research techniques. The quantitative component of this study used chi-square testing for independence, econometric modeling, and Monte Carlo simulations. The relationships between demographic variables, pricing strategies, and perceived management stability were the key items analyzed by these statistical tools. The qualitative component of the research was detailed case studies of industry leaders in the biopharmaceutical arena. Such case

studies offer a contextual basis for understanding how different firms manage their IP and technology transfer processes in varied regulatory environments. Data from both methodologies were then integrated to allow for a more holistic analysis of the factors influencing the success of biologics and biosimilars in different markets.

SUMMARY OF RESULTS

The results of this study provide several important insights into IP management, technology transfer, and market outcomes in the biopharmaceutical industry. The first is that biosimilars do not displace original biologics from the market at discounted prices, despite high development costs for this class of drug. In other words, the price reductions expected due to biosimilar competition have generally not been realized in the U.S., especially for autoimmune disease and oncology therapies. In contrast, significant price decreases and increased market share by biosimilars have occurred in Europe because more favorable IP regimes and legislative actions support them.

The research does uncover the organizational culture and strategic management practices that would mold perceptions regarding pricing strategies and management stability. It shows that demographic factors, such as firm size or market share, are not as important as the strategic choices of management with regard to technology transfer and protection of intellectual property. This finding underscores the need for firms to take a proactive stance MOT so that their strategies for intellectual property are in line with wider business goals.

Moreover, the thesis acknowledges several challenges related to IP management in the biopharmaceutical sector. Such include, negotiating the complex regulatory environment, addressing ethical issues regarding protection of intellectual property in healthcare and innovation vis-a-vis public's access to affordable medication. The research argues in favor of adopting more advanced IP management practices that would encompass effective control strategies and from among data analytics for making informed decisions.

DISCUSSION

Among the primary limitations of this survey is potential sampling bias. The survey was conducted by sending invites over emails online and through professional networks in the pharma space and may or may not fully represent the entire population of professionals in that space. This would have excluded people who are not very active on these networks or do not check their email very often, thus leading to an over-representation of certain groups.

The analysis clearly shows that age, sex, experience, position, and type of working organization significantly influence perceptions of pricing strategies and management stability. Management of technology literature teaches that more experienced and higher-level management respondents tend to have a more positive view of both pricing strategies and management stability. This could be potentially attributed to their greater involvement in decision-making processes and better understanding of organizational strategies. Also, dissatisfaction and perception differences across organization types indicate the structure's impact on employee attitudes. This correspondingly explains why hospital networks and university health systems have higher satisfaction and perceived stability because of the more structured and standardized processes within them. Employee attitudes are influenced by the structure of the organization, as evidenced by variations in satisfaction and perception among different types of organizations. Networks of hospitals and university health systems usually have more structured and standardized processes. As a result, for perceived stability and satisfaction, such organizational setups appear to be more positive environments.

The p-values and confidence intervals for the coefficients indicate that several demographic and organizational variables significantly influence satisfaction with pricing strategy and perceived stability of management style. The statistically significant relationships suggest that these variables have a genuine impact on the respondents' perceptions and are not due to random chance. Furthermore, Monte Carlo simulation was of great importance in the interpretation of the results from the survey of 247 industry professionals, from which important information regarding employee satisfaction, management practices, and perceptions of market competition was drawn. On the other hand, human resource professionals' survey responses included 247 usable questionnaires that were returned from human resource managers at a local hospital not-for-profit response rate based on the calculation method recommended (46.0%). It

points out that the research predicts the probability of alternative levels of employee satisfaction and market outcomes based on survey responses. Because it is of a probabilistic nature, this approach allowed the study to leap from mere description (as basic statistics do) to an examination of how management practice would affect, for example, technology uptake, pricing strategies and market competition.

This discussion section discusses in detail the delicate relationship between technology management, intellectual property rights and pharmaceutical industry regulatory environment with a special reference to biologics and biosimilars. From the findings of the research, very deep insights can be drawn on how these factors together impact market dynamics, innovation and competitive strategies within the industry. In its dependence on advanced technological processes and strong IP management frameworks, the pharmaceutical sector is unique; these are critical to sustaining innovation and market competitiveness. In so doing, this study makes a substantial contribution to the field in uncovering the relationship between these elements. It indicates, for example, that the introduction of biosimilars would bring about large price cuts for biologics, but such an effect has not been uniform across markets, especially in the case of the United States. The reason for this nonuniformity is that it is based on a complex regulatory environment and strategic IP management practice by originator companies.

The inherent complexities of the pharmaceutical industry, especially in biologics and biosimilars management, create the right kind of environment where a study on technology management interacting with IP rights and regulatory settings can be well grounded. This thesis has proven that such elements are not single-standing factors but rather interrelated and together they impact how market forces, innovation paths, as well as competitive strategies for pharmaceutical firms are shaped. Both the regulatory and trade landscapes significantly influence market dynamics for biologics and biosimilars. The analysis emphasizes the different regulatory strategies undertaken by the USA and Europe, which have led to various market situations and results. In Europe, where a less complicated approach has been adopted to approve biosimilars, this has allowed them to enter the market more quickly with more aggressive pricing strategies—which in turn has pulled down biologic prices substantially. On the other hand, because of its stringent regulations and extended approval process, biosimilars had a slower uptake with much less impact on price reductions in the US market.

The research also finds that strategic IP management is important for companies to sustain their competitive advantage in the markets for biologics and biosimilars. Companies that strategically manage their IP, including those that secure patents, extend market exclusivity, protect through trade secrets, are better able to address problems of competitiveness. This is not only a protection of their innovations but also places hurdles for other companies to enter with a major portion applicable to the biosimilars market. The contribution of IP management to innovation is immense. Through the attainment of patents and market exclusivities, companies are able to ring-fence their R&D investments that bring about further innovation. However, this paper brings out vividly the difficulties that could be involved in managing IPs, especially with regard to biosimilars. Since biosimilars are not exact replicas of their reference biologics, they find challenges in obtaining IP protection. This results in cumbersome IP strategies being drawn up that include patent thickets and litigation, consequently hampering competition as well as the delayed entry of biosimilars into the market.

CONCLUSIONS

Survey results are highly useful for managing technology in the pharmaceutical field by revealing areas of employees who are satisfied and dissatisfied. Even though demographic variables do not show significant association with key outcomes that were obtained from this study, the data could be used to suggest probable aspects related to pricing strategies and management practices which might as well be taken into consideration in the future. The effect of other uninvestigated factors has to be analyzed in future research using a qualitative method, which will provide a deeper understanding of the perceptions and experiences of employees.

Various demographic and organizational factors influence the management of technology and pricing strategies in the pharmaceutical field, particularly with respect to biologics. Insight into these factors would enable organizations to adapt their strategies more effectively to enhance satisfaction regarding stability perceptions of their employees. The interplay of these forces merits further research, which should also be designed to craft interventions for boosting organizational performance and employee well-being that future studies will then test. It is still premature to ascertain significant predictors; more research might be needed with a larger sample or more variables included in the analysis. The conclusion synthesizes the key findings of the thesis, based

on an in-depth literature review and rigorous statistical analysis throughout the study. Specifically, new insights about relationships between IP management, regulatory environments, and market dynamics in the context of the pharmaceutical industry have been well established. The following section synthesizes the research carried out on the intricate dynamics of the pharmaceutical industry and technology management (MOT) with specific focus on biologics and biosimilars. In investigating the interplay of IP management with regulatory environment and market dynamics, it has enhanced understanding of how these intricately entwined relationships can be leveraged to propel—and derive value from—technological change. The work thus holds far-reaching implications that transcend a specific sector: its lessons, strategies are applicable across various high-tech sectors.

The research has shown that technology management, with a special focus on IP and regulatory compliance, is key in defining the competition within the biologics and biosimilars markets. Reviewing the literature, effective management for IP is worthy of ensuring protection for innovations with market exclusivity, and favorable environment like continued investment in R&D. Statistical analysis also confirmed that companies which can perform high in managing IPs and innovating technology will be better placed to sustain their competitive advantage and thrive within the marketplace. One of the key findings of this research is that regulatory environments have a real impact on market dynamics. The paper explicitly compared regulatory frameworks in the United States and Europe, bringing to light that the European environment fosters earlier biosimilar uptake than in the United States. As a result, biosimilars manufacturers have adopted more aggressive pricing strategies and realized higher market shares in Europe against slower adoption and less dramatic price changes in the United States. The study further confirmed the importance of technological improvements within the pharmaceutical sector. Investment by companies in advanced manufacturing and quality control analytic techniques ensure that they are able to meet regulatory requirements, keep up the quality of their products, and realize cost efficiencies (all of which are important variables for competition in the biosimilars market). The results indicate that technological innovation with effective IP management is a major driver for success in this industry.

APPLICABILITY OF THE RESULTS AND LIMITATIONS OF THE RESEARCH

One of the primary limitations of this survey is, potentially, sampling bias. The survey was distributed online through email invites and professional networks in the pharma field, which may or may well not represent the whole population of professionals in that field. This would exclude individuals not active on these networks or who do not check their email often. It could lead to over-representation of certain groups.

Impact: The findings cannot be generalized to all pharmaceutical industry professionals. As a result of this, specific subgroups such as professionals in smaller or less connected organizations are underrepresented. It will also be difficult to make correct inferences about underrepresented groups.

Response Rate: Although the survey elicited 247 responses in total, it is lowly to respond that a high response rate is important since response rate can always introduce non-response bias where the views of non-respondents might be different systematically from those who responded because probably non- respondents have different views or experiences as well. The voices of non-respondents could have been those critical insights that are missing and this could affect how complete the findings are.

Self-Selection Bias: This survey was voluntary, which is a probable cause of self-selection bias. People might have a tendency to respond to it more in case they hold strong opinions or have had experiences that make them more (or less) likely to respond, thus biasing the results. The views of those employees who were very satisfied or dissatisfied may be overrepresented in the survey. It would mean the experiences of those moderately (or indifferent) satisfied are underestimated.

Limited Geographic Scope: The survey covered a vast area in the USA but not all. Variations in regional practices, regulations, and market dynamics can have important implications for perceptions and experiences in the pharmaceutical area. Survey results may be less generalizable to regions not well represented in the survey.

Demographic Imbalances: Despite the survey involving a variety of demographic categories, some groups may be imbalanced, like age, sex or experience level and this can influence the results at large as well as the ability to generalize to specific subgroups.

Survey Design Limitations: The survey questions were overly comprehensive in measuring the various aspects of technology management, pricing strategies, and organizational culture but might

not be fully relevant. Respondents' answers can also be influenced by the phrasing of questions. The wording and structure of the question might provoke misconceptions or a bias response.

Future research might consider increasing sample diversity and reaching more centers and varied geographic areas. Improving response rates with follow-up reminders was done. Encouraged more participants, even those with views that were moderate. The survey conducted among pharmaceutical professionals gave the following key insights into technology management, pricing strategies, and organizational culture. As to the main findings, there was a balanced distribution across age groups, a slight female majority, and varied levels of experience. Most respondents were from an upper management level and worked in single private/independent pharmacies or hospital networks. A notable proportion of the respondents disagreed or strongly disagreed (36.4% combined) with the stability of the management style. This expresses some resentment about the practice of management. Monte Carlo simulation results showed "neutral" and "very satisfied" to be likeliest outcomes concerning satisfaction with the pricing strategy, although "dissatisfied" and "very dissatisfied" had substantial proportions as well.

A substantial proportion of respondents (combined 36.4%) disagreed or strongly disagreed regarding the stability of the management style, hence expressing mixed feelings concerning management practices. According to the results of the Monte Carlo simulation, very neutral and very satisfied are most likely outcomes for satisfaction with the pricing strategy. Two extreme categories, dissatisfied and very dissatisfied, however, also had significant proportions.

The implications of the survey findings are vital for any technology management in the pharmaceutical field: because satisfaction with pricing strategies is rather low, firms are urged to review and improve their pricing models. This could mean better articulation of price benefits, more transparent pricing structures, and initiatives for customer advocacy or engagement. Also in relation to technology management: feelings toward management stability were mixed, which means that an organization should work on creating a more supportive and predictable management environment. This may involve clear communication of policies, uniform leadership practices, and building a culture that propagates stability and trust. Even though no significant associations were revealed between demographic variables and levels of satisfaction, diversity in the needs and preferences of employees is good. It is advantageous to have tailored approaches that take into account specific issues or expectations; this helps boost employee satisfaction overall. The absence of strong associations in the inferential statistics indicates that other factors

are likely to be influencing employee perceptions. Organizational culture, workload, job satisfaction, and very specific managerial practices. All to be considered in future research to make sure this gets right. This is to be achieved by organizations putting in place regular surveys and feedback channels for monitoring satisfaction of employees and perceptions through time, which in return will facilitate early issue identification and continuous improvement of management practices. Quantitative findings can be effectively complemented by using research methods such as interviews or focus groups to bring out a deeper insight into why employees have a given perception or experience. It is through this mixed-methods approach that one arrives at more holistic and practical strategies.

The survey yielded some insightful understanding of the current technology management, pricing strategies, and organizational culture condition in the pharmaceutical field. Both with some good points to take pride in— since some respondents are very content— and those that call for significant growth, especially pricing strategies and management stability. After using this to solve these challenges (and conducting future research), it will be instrumental in helping these firms improve their management practices: this will consequently bring about higher levels of employee satisfaction, and overall organizational effectiveness.

The key findings of this research underline how vital proper technology management, specifically in the areas of IP and regulatory compliance, is in altering the competition within biologics and biosimilars markets. Review of literature supported by robust statistical analysis confirmed effective IP management to be vital for: protection of innovations that lead an organization to a successful path; ensuring market exclusivity which encourages sustained investment in research and development (risky if products are not protected through patents); elements that become most important for remaining competitive in light of heavy demand within any dynamic environment.

One of the most important revelations of this research is how deeply regulatory environments can come to bear upon market dynamics. The paper went on in great detail to compare American and European regulatory frameworks with a shocking discovery: that the European system of regulations happens to be what enables the rapid uptake of biosimilars on their market. Such an environment has encouraged more aggressive pricing strategies and a higher share-of-market for biosimilars in Europe; in this case, uptake has been much slower and price reductions less marked, as observed from the US setting. Such findings really underscore

how critical it is for regulation to be aligned with market dynamics— all these being aimed at enhancing competition as well as fostering innovation.

Moreover, the study has brought out the essentiality of technological improvements in the pharmaceutical field. Companies which invest in advanced manufacturing practices and analytical techniques of highest levels are enabled to meet regulatory requirements that are very stringent, uphold high product quality and also attain cost efficiencies — these are important capabilities for effective competition in the biosimilars market. The findings indicate that technological innovation (when complemented by strategic IP management) acts as a great force to drive success within this high-stakes competitive industry.

The Unique Contribution of the Research to Management

This dissertation contributes to the management field by analyzing in depth how strategic management of MOT and IP impacts the commercialization and market success of biologics and biosimilars. Not only does it compare regulatory frameworks between the United States and Romania but also draws implications for markets worldwide. Integrating MOT with IP management, the research presents a solid framework useful for industry practitioners and policymakers to enhance technology transfer initiatives, frame market entry strategies effectively, and promote innovation in the biopharmaceutical industry. It stresses that IP strategy should be aligned with broader technological and business objectives to ensure competitive advantage and sustainable growth for markets that host their products as well as those of other industries.

Future Recommendations with Policy Changes Proposals

Based on the extensive survey data, a number of recommendations are made that can help improve management in the area of technology and innovation at the pharmaceutical sector to enhance overall employee satisfaction. These recommendations relate to the critical aspects of training, structure of the organization, communication and information sharing and ethical principles (that have important value) for a proven management capability technology.

Technology management emphasizes that employee training is key to providing staff with the skills necessary to understand complicated pricing strategies and effectively handle customer relationships. The results of the survey reflect a definite need for extensive training programs that focus on discount management. The net result of ensuring all employees are extensively trained in managing their discounts is an increase in overall satisfaction with pricing strategies. A well-informed staff is better able to help customers in a more expeditious manner while streamlining the discount process, and therefore reducing conflicts of interest as far as ambiguities in pricing are concerned. In addition, such continuous management training has to be implemented by stressing stability and at the same time innovation; these will form a base for management, thus enhancing employees' perception of leadership which increases their satisfaction and commitment to organizational goals.

On the other hand, survey data uncovers separate preferences among different age groups. The results thereby obtained indicate that a uniform strategy is not going to be helpful in meeting very diversified needs. Younger employees, for example those between 25 and 40 years of age, tend to place value on innovation and flexibility within their work environment. On the other hand, older employees between the ages of 41 to 60 seek stability along with open communication. Data analysis has proven that adapting management strategies according to these generational preferences can drastically improve job satisfaction for all. Respecting these different expectations will help build an inclusive and supportive organization. The result is ultimately leading to higher productivity and lower turnover rates. Further, a more extensive range of geographical locations and organizational types would be included to ensure a generalized view of the factors influencing satisfaction and management perceptions. This, in particular, is key to understanding the implications at a global level regarding technology management practices and the impact variation levels of intellectual property rights have on different regions. A more extensive set of geographical locations and different types of organizations would paint a complete picture of what influences satisfaction and perceptions of management. The global implications of technology management practices and the impact of intellectual property rights that vary by region are issues for which such broad data is particularly important.

Moreover, an equilibrium in management style to blend commitment with change and vibrant involvement of resources is what drives a productive and content workforce. The

research implies that staff excel in settings where decision-freedom is loose, and they have a say in strategic plans. Developing policies to support such management can breed innovation while keeping the discipline that would be demanded of long-run interests. Such a stride also fits into wider goals of technology management where flexibility (and constant refurbishment) is pivotal to maintaining competitiveness, considering how quickly the pharmaceutical terrain is swiveling.

Technology management also underlines that effective communication is the be-all and end-all of successful management. The survey further underlines the need for strong communication channels through which employees can give their feedback on management actions and pricing strategies. Equally important is the regular review and action of this feedback to ensure that specific concerns of employees are taken up on time, hence building a trustful and transparent culture. In technology management, clear communication supports the effective rollout of new technologies as well as seamless integration with innovative practices introduced within the organization. The development and dissemination of clear guidelines and ethical standards is at the core of sustaining a fair and transparent work ambiance. Survey data shows that employees are likely to trust and cooperate with management if they see these principles implemented. The enforcement of competitive actions through well-drawn guidelines can do much in building the reputation of the organization and providing a background for its intellectual property rights. This is very important in the pharmaceutical industry since intellectual property protection is what paves the way for an organization to come up with new ideas over which it can compete effectively.

Based on the survey, the following are some of the future research directions that would help in fine-tuning technology management practices and enhancing employee satisfaction in the pharmaceutical industry. The rapid rise of new technologies— among them artificial intelligence and automation— shall be duly considered with regard to their impact on employee satisfaction alongside management practices. These future research directions are oriented to a more profound understanding of the factors that affect technology management, thus providing a more substantial evidence base upon which policies and strategies can be built. Longitudinal studies must be used to understand fully how management practices relate to employee satisfaction, as well as technology management over time. This is because they have steady controls that show trends and the sustained impact that implemented changes have. This will help to better understand the fine-tuning of evolving management strategies and their impacts within dynamic

technology environments. It is important to appreciate how these technologies come into play at the workplace in order to inform robust technology management strategies that will enhance innovation while taking good care of the employees' welfare.

Culture is crucial in effecting employee job satisfaction and perceptions of management. Such future studies would be interested in identifying the most contributing cultural attributes that drive positive outcomes with an objective to create a supportive and engaging work environment. This issue ties directly into technology management because a strong organizational culture will greatly enhance the adoption of new technologies as well as safeguard intellectual property. The insight on how customers perceive employee training results provides the basis for refining strategies of employee involvement in improvement activities, which are directed at achieving product quality and service standards desired by customers. Thereafter, this can be used to bring internal practices in line with external expectations to position business competitively.

In conclusion, future research should be considered on policy changes and regulatory environment that can create impact on technology management. This is especially due to the external regulations that have a heavy hand on the pharmaceutical sector. In this consideration, it is important for any set strategies to have incorporated aspects that show how internal practice is shaped by these external factors to comply with legal requirements as well as organizational goals. The study of policy, regulation and Technology Management interplay would help organizations to better steer through intricacies of a pharmaceutical landscape, fueling innovation. The external regulations render the pharmaceutical industry highly sensitive, then the ability to understand how these extrinsic factors influence internal activities becomes vital in order to craft strategies in alignment with legal imperatives and organizational goals. Through investigating the interrelationship with policy, regulation, and technology management, organizations can disentangle some of the knots that make up the complex pharmaceutical landscape, enhancing their ability to innovate.

By implementing these recommendations and undertaking the future research directions that follow, pharmaceutical organizations can strongly enhance the management of technology within their fold, subsequently improving employee satisfaction and furthering the cause of increased protection for intellectual property, as well as more successful market share both locally and internationally. The survey results and analysis that follow are unique in that they

make an in-depth examination concerning the current state of technology management within the pharmaceutical industry, thus offering valuable information about areas in most urgent need of improvement and further research. These findings have substantial implications for industry practitioners and policymakers. From an industry perspective, it underscores the need for a strategic approach towards the management of IP and technological innovation. Companies which are able to protect their innovations effectively, steer through the regulatory environment and invest in advanced technologies are likely to be successful in competitive biologics and biosimilars markets. Such an act calls for proactive management of IP by building patent thickets along with heavy reliance on trade secrets and other tools to preempt competitors from entering. Policymakers, according to the study, should initiate reforms favoring competition and innovation within the pharmaceutical sector. This would mean going back to the regulatory framework to ensure it is not very demanding and also creating an environment that would see biosimilars being developed and adopted. The policymakers had to strike a balance between public health interests and those of competition and innovation (which would ensure access to affordable medicine).